Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

The Prostate
Masanori NoguchiKei Matsuoka

Abstract

The safety, toxicity, and immunological response of individualized peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose of estramustine were evaluated. Sixteen patients with HLA-A24+ HRPC were enrolled in the phase I/II study. Conducted immune monitorings for those patients were peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by interferon-gamma production and peptide-reactive immunoglobulin G (IgG) by an enzyme-linked immunosorbent assay. Clinical responses and quality of life (QOL) outcomes using a self-reported patient questionnaire were also evaluated. Vaccinations were well tolerated, but all patients developed grade 1 or 2 local redness and swelling at the injection site. There was no significant immunosuppression in most cases when the peptide and a half dose (280 mg/day) of estramustine were administrated. Augmentation of peptide-specific CTL precursors or peptide-specific IgG was observed in 10 of 14 or 7 of 14 patients at 12 weeks (peptide vaccination alone), and in 6 of 8 or 10 of 12 patients at 24 weeks (during the combination therapy), respectively. All 13 patients treated, with the combination therapy, showed a ...Continue Reading

References

Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R HudesC McAleer
Jul 1, 1999·The Prostate·B A TjoaG P Murphy
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K KellyH Scher
Nov 15, 2002·Nature·Hiroaki Kitano
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Randall MillikanChristopher J Logothetis
Sep 5, 2003·International Journal of Clinical Oncology·Mamoru HaradaKyogo Itoh
Feb 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takashi MineHideaki Yamana

❮ Previous
Next ❯

Citations

Jun 23, 2009·Der Urologe. Ausg. A·M A ReiterA Haferkamp
Mar 5, 2008·Cancer Immunology, Immunotherapy : CII·Dirk Nagorsen, Eckhard Thiel
Sep 26, 2008·Cancer Immunology, Immunotherapy : CII·Chih-Wen TsengT-C Wu
Dec 1, 2012·Cancer Immunology, Immunotherapy : CII·Masanori NoguchiKyogo Itoh
Apr 2, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sarfraz AhmadGerald C O'Sullivan
Dec 22, 2007·Nature Reviews. Immunology·Laurence ZitvogelGuido Kroemer
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip M ArlenWilliam Dahut
Nov 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M LubaroffRichard D Williams
Jun 5, 2008·The Journal of Clinical Investigation·Laurence ZitvogelGuido Kroemer
Aug 24, 2012·Expert Review of Vaccines·David M Lubaroff
Jul 31, 2012·Antiviral Research·Peng Peng IpToos Daemen
Jul 29, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S SchmidC Rothermundt
Dec 1, 2009·Neurosurgery Clinics of North America·James L FrazierAlessandro Olivi
Jan 27, 2009·Advanced Drug Delivery Reviews·David M Lubaroff, Dev Karan
Dec 7, 2007·European Urology·Andrea KiesslingMarc Schmitz
Sep 21, 2006·Cancer Science·Kyogo Itoh, Akira Yamada
Oct 31, 2012·Cancer Science·Akira YamadaKyogo Itoh
Mar 5, 2016·Expert Opinion on Biological Therapy·Shijoro SakamotoTetsuro Sasada
Dec 25, 2012·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mizuhiko TerasakiKyogo Itoh
Jun 1, 2017·Nature Reviews. Urology·Takahiro KimuraHirotsugu Uemura
Jun 15, 2007·International Reviews of Immunology·Uriel M Malyankar
Sep 9, 2017·Future Science OA·Eleftheria A Anastasopoulou, Ioannis F Voutsas
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohamed S ArredouaniMartin G Sanda
Sep 21, 2006·Bioconjugate Chemistry·Alison A McCormickGregory P Pogue

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.